Phase 2 clinical trial ongoing in Korea67%
Completion of US FDA phase 1/2 clinical trial67%

Preventive treatment of bronchopulmonary dysplasia(BPD)

PNEUMOSTEM® an allogeneic umbilical cord blood-derived mesenchymal stem cell product, is currently under development for the preventive treatment of Bronchopulmonary Dysplasia(BPD) in premature infants. Currently, Phase 2 clinical trial is ongoing in Korea and PNEUMOSTEM® has been Orphan Drug designated by US FDA and EMA. Recently, US FDA granted a Fast Track Designation for PNEUMOSTEM®.

· Product :PNEUMOSTEM®
(human Umbilical Cord Blood-derived
Mesenchymal Stem Cells)
· Manufacturer :MEDIPOST Co., Ltd.
· Indication :Preventive treatment of
Bronchopulmonary Dysplasia(BPD)
· Route of Administration :Intra-tracheal administration

Mechanism of Action for PNEUMOSTEM®

Research results
· Anti-apoptosis : Chang et al(2009) Cell transplant. 18:869-86, Sung et al(2015) PLoS One. 8:e1035574, Chang et al (2013) PLoS One 1:e52419
· Anti-inflammation : Jin et al(2013) Int. J. Mol. Sci. 14: 17986-18001, Kwon et al(2019) Int J Mol Sci. 2019 Sep 27;20(19). pii: E4815, Kim et al(2020) Stem Cells Int. Article ID 1802976
· Regeneration of Lung specific cell : Chang et al (2014) Am J Respir Cell Mol Biol. 3: 391-9, Ann et al(2015) Cytotherapy 8: 1025-35